T. Goto

Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines.

T. Kitamura, K. Kawabe, Makoto Suzuki, 1999, Cancer letters.

Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma.

Y. Homma, T. Kitamura, K. Kawabe, 1997, The Journal of urology.

Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation

T. Kitamura, K. Kawabe, H. Matsushima, 1999, Cancer.

The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer LNCaP cells

Ken Takeda, K. Takeda, T. Kitamura, 1999, International journal of urology : official journal of the Japanese Urological Association.

Differences in cell kinetic changes among renal cancer cell lines treated with interferon‐α

T. Kitamura, Y. Hosaka, H. Matsushima, 2001, International journal of urology : official journal of the Japanese Urological Association.

Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance.

Y. Homma, T. Kitamura, A. Sakamoto, 1998, Human pathology.

Prominent induction of cyclin B1 in G2/M renal cancer cells with butyrolactone 1

T. Kitamura, Y. Hosaka, H. Matsushima, 2003, International journal of urology : official journal of the Japanese Urological Association.

1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

M. Buyse, M. Parmar, D. Dearnaley, 2022, Annals of Oncology.